An updated systematic review of dozens of studies finds that Ginkgo biloba may offer modest short-term improvements for people with dementia, but shows little to no benefit for individuals with ...

Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...

Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to ...

Shares of Ginkgo Bioworks fell after the company reported lower fourth-quarter revenue and said it would sell its biosecurity business in exchange for a minority equity position in the business. The ...

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with ...

Ginkgo showcased a flagship collaboration with OpenAI that linked GPT‑5 as an “AI scientist” to its autonomous lab. On a cell‑free protein synthesis challenge, the system delivered a 40% performance ...

Ginkgo Bioworks DNA shares are down following the company’s fourth-quarter and full-year 2025 financial report. The stock’s decline comes as the company is focusing on investing in autonomous labs.

Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging. Likewise, the company's ambitions of high efficiency have yet to ...

Add Yahoo as a preferred source to see more of our stories on Google. This undated photo shows a ginkgo leaf in New Paltz, NY. In addition to their fan shape, leaves of ginkgo trees have a unique ...

Behzad Mahdavi, Senior Vice President Biopharma Manufacturing & Life Sciences Tools at Ginkgo Bioworks. Cell and gene therapies may be the most anticipated invention of this century. For many people, ...